Product Description
ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tolerability in adults with obesity. (Sourced from: https://firstwordpharma.com/story/7079628)
Mechanisms of Action: GIPR Antagonist, GLP-1 Agonist
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alveus Therapeutics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Obesity|Overweight|Type 2 Diabetes|Weight Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07399678 |
ALV-102-1 | P1 |
Recruiting |
Weight Loss|Obesity|Overweight|Type 2 Diabetes |
2027-04-01 |
50% |
2026-02-12 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|